MedTrace Logo

Nature-based Therapy Program for Parkinson's Disease (PARC)

NCT06452043 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-12-06

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a nature-based program has positive effects on the physical and psychosocial health in a group of participants with Parkinson's disease. The main questions it aims to answer are:

Will the program improve:

* The physical outcomes such as mobility, strength and balance?
* The psychosocial health outcomes?

Participants will:

* Be assessed before and after the program;
* Participate in one session per week of the intervention.

Conditions

Interventions

OTHER

PARC program

Activities in nature such as walking, exercises (strengthening, mobility, balance), pedal boat, yoga, dance, mindfulness, meditation, forest bathing or Shinrin-Yoku, interpretation of nature

Sponsors & Collaborators

  • Réseau Parkinson Québec

    collaborator UNKNOWN

  • McGill University

    collaborator OTHER

  • Fonds de la Recherche en Santé du Québec

    collaborator OTHER_GOV

  • Université du Québec à Chicoutimi

    lead OTHER

Principal Investigators

  • Rubens da Silva, PhD · Université du Québec à Chicoutimi

  • Marie-Ève Langelier, MD · Université du Québec à Chicoutimi

  • Émilie Fortin, PT · Université du Québec à Chicoutimi

  • Mireille Cliche, SW · Université du Québec à Chicoutimi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2024-10-07
Completion
2024-10-07

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06452043 on ClinicalTrials.gov